Monograph Details
|
|
Respiratory Tract
> Rhinitis/rhinorrhea (intranasal products)
|
|
NASAREL |
| Manufacturer |
|
Teva Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Flunisolide 25micrograms/spray; aqueous nasal spray. |
| Indications |
|
Seasonal or perennial rhinitis. |
| Children |
|
<6yrs: not recommended. 6–14yrs: initially 1 spray in each nostril 3 times daily or 2 sprays in each nostril twice daily; max 4 sprays/nostril per day. |
| Adults |
|
≥15yrs: initially 2 sprays in each nostril twice daily; may increase to 2 sprays in each nostril 3 times daily; max 8 sprays/nostril per day. |
| Contraindications |
|
Untreated nasal infections. |
| Precautions |
|
Reduce dose as condition improves. Reevaluate if no response after 3 weeks. Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. May use decongestants if needed. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Aftertaste, nasal burning/ stinging/ dryness, epistaxis, pharyngitis, hoarseness, cough, nausea, abnormal sense of smell, reduced growth velocity in children. |
| How Supplied |
|
Spray—25mL (200 sprays) |
|
|
|
|
